Characterisation of the Inflammatory Profile in Eosinophilic and Neutrophilic Inflammatory Phenotypes in Patients with Chronic Obstructive Pulmonary Disease GOLD III
Abstract
Current concepts of chronic obstructive pulmonary disease (COPD) are based on the identification of clinically relevant phenotypes and inflammatory endotypes, enabling the identification of patient groups with different disease characteristics, prognoses and therapeutic targets. Particular attention is paid to eosinophilic and neutrophilic inflammatory phenotypes, which may differ in the nature of the inflammatory response and the levels of individual pro-inflammatory mediators. One of the promising markers of systemic inflammation in COPD is interleukin-6 (IL-6), the level of which may reflect specific features of the inflammatory response associated with different predominant inflammatory phenotypes. Objective — to assess between-group differences in serum IL-6 concentrations and fractional exhaled nitric oxide (FeNO) levels, as well as the relationship between these parameters, in patients with stable COPD GOLD III, clinical group E, according to the inflammatory phenotype. Materials and methods. The inflammatory phenotype of patients with COPD was determined based on peripheral blood eosinophil counts. Patients were divided into two groups: an eosinophilic inflammatory phenotype (eosinophil count ≥ 300 cells/µL) and a neutrophilic inflammatory phenotype (eosinophil count < 300 cells/µL). Serum IL-6 concentration (pg/mL) was determined using enzyme-linked immunosorbent assay (ELISA) with reagents supplied by Bender MedSystems GmbH (Vienna, Austria). According to the established criteria, 60 patients with COPD GOLD III, clinical group E, in a stable state were divided into two groups: 17 patients with an eosinophilic inflammatory phenotype and 43 patients with a neutrophilic inflammatory phenotype. FeNO was additionally assessed using a standardised method in accordance with the recommendations of the American Thoracic Society and the European Respiratory Society (ATS/ERS), with a portable electrochemical analyser NIOX VERO (Circassia AB, UK). Results and discussion. In patients with COPD GOLD III, clinical group E, the neutrophilic phenotype was characterised by a significantly higher serum IL-6 concentration compared with the eosinophilic phenotype (11.4 ± 1.2 vs. 4.3 ± 0.6 pg/mL; p < 0.05), whereas the eosinophilic phenotype demonstrated significantly higher FeNO values (33.7 ± 3.1 vs. 23.6 ± 2.7 ppb (parts per billion); p < 0.05). The study results demonstrated phenotypic differences in the systemic and local inflammatory responses in patients with COPD. An association between serum IL-6 levels and FeNO was identified, with the nature of this relationship differing according to the inflammatory phenotype. Combined assessment of the pleiotropic cytokine IL-6 and the local marker FeNO may represent a promising direction for further research aimed at a more detailed study of the interrelationships between different components of the inflammatory process and expanding the possibilities for laboratory characterisation of different COPD phenotypes. Conclusions. In patients with COPD GOLD III, clinical group E, in a stable state, the mean serum IL-6 concentration in the neutrophilic inflammatory phenotype was 11.4 ± 1.2 pg/mL, while FeNO was 23.6 ± 2.7 ppb. In the subgroup with paired measurements (n = 10), a moderate positive correlation was found between IL-6 and FeNO (r = 0.65; p ≈ 0.042). The identified association between systemic and local inflammatory activity reflects specific features of the inflammatory profile in the neutrophilic phenotype of COPD.